Multiple Myeloma Segmentation
Drug Class (Proteasome Inhibitors, Immunomodulatory Drugs, Steroids, Monoclonal Antibodies)
The immunomodulatory drugs segment is expected to hold 38% share multiple myeloma market during the forecast period. Oral immunomodulators are recognised as a new therapy and are believed to be extremely successful in enhancing the course of treatment for a number of tumours. The immunomodulators category consequently controlled a disproportionately high part of the global market due to these drugs' strong revenue positions. For instance, 2,625 new cases of multiple myeloma are expected to be diagnosed in Australia in 2022, according to data given by Cancer Australia. The same source also claims that a person's chance of receiving a multiple myeloma diagnosis by the time they are 85 years old is 1 in 111, or 0.90 percent.
Distribution Channel (Hospital, Retail, Online Pharmacies)
The hospital segment is expected to hold around 45% share of the global multiple myeloma market during the forecast period. Generally, the medicine used to treat this condition can, at least once a year, be recommended and given in hospital settings. This will make it possible to follow treatment guidance in multiple myeloma and also the proper administration of life-saving therapeutics. These factors are leading the hospital segment for multiple myeloma treatment market.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Therapy |
|
|
Distribution Channel |
|
